Chemistry:Zervimesine
Zervimesine (INN, USAN;[1] developmental code name CT-1812 OR CT1812; tentative brand name Elayta) is a sigma σ2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications.[2][3][4]
The sigma σ2 receptor is a binding site for β-amyloid oligomers.[4] Zervimesine has been found to diplace β-amyloid oligomers from the sigma σ2 receptor in both preclinical and clinical studies.[4] As of 2024, effectiveness data on zerimesine for treatment of Alzheimer's disease are still lacking.[4]
Zervimesine is under development by Cognition Therapeutics.[2] As of July 2025, it is in phase 2 clinical trials for Alzheimer's disease, dementia, and dry age-related macular degeneration and is in preclinical research for Parkinson's disease.[2] The drug was also being developed for treatment of other cognition disorders, but development for this indication was discontinued.[2]
See also
References
- ↑ "Proposed INN: List 133 International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO Drug Information 39 (2). 2025. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf.
- ↑ 2.0 2.1 2.2 2.3 "Cognition Therapeutics". 14 July 2025. https://adisinsight.springer.com/drugs/800043460.
- ↑ "Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist". Clinical Therapeutics 46 (11): e21–e28. 2024. doi:10.1016/j.clinthera.2024.08.013. PMID 39289058. https://linkinghub.elsevier.com/retrieve/pii/S0149291824002224. Retrieved 27 July 2025.
- ↑ 4.0 4.1 4.2 4.3 "CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer's Disease Treatment: A Systematic Review of Available Clinical Data". Journal of Alzheimer's Disease 101 (s1): S115–S128. 18 October 2024. doi:10.3233/JAD-230994. PMID 39422939. https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-230994. Retrieved 27 July 2025.
 |  |
